C. Willekens

Sort by:

External loads on the limbs of jumping horses at take-off and landing.

H C Schambardt, Hedda Merkens, V. Vogel, C. Willekens
American journal of veterinary research
1993

Using a force plate, ground reaction force (GRF) patterns at take-off and landing between the hooves and the ground were recorded for all limbs of 5 Dutch Warmbloods jumping a 0.8-m vertical fence… (More)

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Eytan M. Stein, Courtney D Dinardo, +24 authors Martin S. Tallman
Blood
2017

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in… (More)

Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia

J. L. Rossignol, A S Michallet, +7 authors Loïc Ysebaert
Leukemia
2011

We report our experience on rituximab–cyclophosphamide–dexamethasone (RCD) combination therapy for the treatment of autoimmune disorders (AIDs) in 48 chronic lymphocytic leukemia (CLL) patients.… (More)

An Unusual Case of Constitutional Mismatch Repair Deficiency Syndrome With Anaplastic Ganglioglioma, Colonic Adenocarcinoma, Osteosarcoma, Acute Myeloid Leukemia, and Signs of Neurofibromatosis Type…

Badih Daou, Marc Zanello, +10 authors Georges Abi Lahoud
Neurosurgery
2015

BACKGROUND AND IMPORTANCE Constitutional mismatch repair deficiency (CMMRD) syndrome is a disorder with recessive inheritance caused by biallelic mismatch repair gene mutations, in which mismatch… (More)

CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model

Y. Zhang, S. Patel, +16 authors Fawzia Louache
Cell Death and Disease
2012

The chemokine receptor CXCR4 favors the interaction of acute myeloid leukemia (AML) cells with their niche but the extent to which it participates in pathogenesis is unclear. Here, we show that CXCR4… (More)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Johanna Mondésir, C. Willekens, Mehdi Touat, Stéphane de Botton
Journal of blood medicine
2016

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas… (More)

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.

C. Willekens, Odile Blanchet, +8 authors Nicolas Boissel
Haematologica
2016

In t(8;21)(q22;q22) acute myeloid leukemia, the prognostic value of early minimal residual disease assessed with real-time quantitative polymerase chain reaction is the most important prognostic… (More)

Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case report

C. Willekens, Aurélie Cornélius, M. Guerry, Agnés Wacrenier, François Fourrier
Journal of medical case reports
2011

INTRODUCTION Hemophagocytic lymphohistiocytosis induced by viral diseases is a well recognized entity. Severe forms of H5N1 influenza are known to be associated with symptoms very similar to a… (More)

Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.

Nicolas Duployez, C. Willekens, Alice Marceau-Renaut, Elise Boudry-Labis, Claude Joseph Preudhomme
Expert review of hematology
2015

Core-binding factor acute myeloid leukemia (CBF-AML) - including AML with t(8;21) and AML with inv(16) - accounts for about 15% of adult AML and is associated with a relatively favorable prognosis.… (More)

Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.

Laure Ricard, Noémie Abisror, +8 authors A Mekinian
Leukemia & lymphoma
2018

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences